Novartis Ventures et al. in £8.65m round for ITS
Novartis Ventures, Sweden’s HealthCap, France’s Truffle Capital and London Technology Fund, have participated in a £8.65m funding round for British biotech company Immune Targeting Systems (ITS).
More on Healthcare
BlackRock mulls new vintage of private capital products for sophisticated retail investors in Europe
Global asset manager explores new generation of private market funds for wealthy individuals banking on positive uptake from retail investors
LDC outlines plans for new record year of deployment
Despite macro woes, sponsor wants to build up on last year’s pace of investment and exceed GBP 400m mark in 2023
GP Profile: Key Capital upbeat about SME deals with next fund in the making
UK small-cap sponsor could return to market for its next GBP 125m fund at the end of 2023
21 Invest France eyes EUR 300m Fund VI target by year-end
Fund VI has raised half of its target so far, with the GP seeking to further prove its investment track record throughout 2023
Latest News
McDermott adds to German PE team with Noerr and Latham duo
Noerr’s Holger Ebersberger and Latham & Watkins’ Hanno Witt to join the firm’s Munich office
MML launches lower-mid-market strategy for UK, Northern European B2B assets
London-headquartered GP invested in AI provider MIcompany in first deal for new strategy this week
Revo Capital preps third fund for 2023 launch
VC firm aims to raise USD 75m-150m from private and public investors including blue-chip institutional LPs in Europe, MENA and US
Oakley raises EUR 2.85bn for fifth flagship fund
More than twice the size of its 2019 predecessor, the vehicle will allow for larger equity tickets, more investments and bolt-ons